Yazar "Demir, Nazan" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim
    Öğe
    Factors affecting survival in retroperitoneal sarcomas treated with upfront surgery: A real-world study by Turkish Oncology Group
    (Akad Doktorlar Yayinevi, 2021) Akagündüz, Baran; Akın Telli, Tuğba; Yıldırım, Hasan Çağrı; Göksu, Sema Sezgin; Demir, Nazan; Hafızoğlu, Emre; Özer, Muhammet; Çevik, Gökçen Tuğba; Sakin, Abdullah; Göktaş Aydın, Sabin; Şengül Samancı, Nilay; Özyurt, Neslihan; Atçı, Muhammed Mustafa; Ayhan, Murat; Turan, Merve; Sarıyar, Nisanur; Karaçin, Cengiz; Kılıçkap, Saadettin; Paydaş, Semra; Doğan, Mutlu
    Retroperitoneal sarcomas (RPS) account for approximately 15% of all soft tissue sarcomas (STS) and encompass a heterogeneous group of tumors with limited multimodality treatment options. Surgical resection with negative margins remains the standard primary treatment for patients with localized RPS. In this multicenter study, we aimed to demonstrate the real-world data on factors affecting survival in RPS treated with upfront surgery. We included a total of 197 patients who underwent curative-intent resection of a primary non-metastatic RPS between 2000-2020 at ten experienced medical oncology departments in Turkey. The median follow-up was 33 months. The median age of patients was 53 years, 57.4% of patients were female. Univariate analysis revealed that; tumor size, grade, necrosis, resection margin status, were factors affecting recurrence-free survival (RFS) (p= 0.002, p= 0.044, p= 0,024, p= 0.003 respectively). Age, tumor size, stage, resection margin status were factors affecting overall survival (OS) (p= 0.038, p= 0.001, p= 0.032, p< 0.001, respectively). In multivariate analysis, tumor size and resection margin status were independent factors affecting RFS and OS (all p-values < 0.05). Our study demonstrated that tumor size, and resection margin status were the main factors affecting survival in resected RFS. In comparison, adjuvant chemotherapy (CT), radiotherapy (RT), or multimodality treatment did not show OS and RFS advantages. We believe that advances in the molecular characterization of these tumors might help clinicians to detect the best candidates for adjuvant therapies in RPS.
  • Küçük Resim
    Öğe
    Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2- negative advanced gastric cancer
    (Asian Pacific Organization for Cancer Prevention, 2014) Bilici, Ahmet; Selçukbiricik, Fatih; Demir, Nazan; Öven Ustaalioğlu, Bala Başak; Dikilitaş, Mustafa; Yıldız, Özcan
    Background: Docetaxel and cisplatin in combination with fluorouracil (DCF) regimen is accepted to be one of the standard regimens in the treatment of advanced gastric cancer. However, substantial toxicity has limited its use in daily clinical practice. Therefore, modification of DCF regimens, including introduction of capecitabine has been investigated to improve the safety profiles. In the present study, the efficacy and toxicity of a regimen with a modified dose of docetaxel and cisplatin in combination with oral capecitabine (DCX) was evaluated in untreated patients with HER2-negative advanced gastric cancer. Materials and Methods: Fifty-four patients with HER2-negative locally advanced or metastatic gastric cancer were included in this cohort. Patients received docetaxel 60mg/m2 plus cisplatin 60mg/m2 (day 1) combined with capecitabine 1650mg/m2 (days 1-14) every 3 weeks. Treatment response, survival, and toxicity were retrospectively analyzed. Results: The median age was 54 years (range: 24-76). The majority of patients (70%) had metastatic disease, while 11 patients (21%) had recurrent disease and underwent curative gastrectomy, and 5 patients (9%) had locally advanced disease (LAD). The median number of DCX cycles was 4. There were 28 partial responses and 11 complete responses, with an overall response rate of 72%. Curative surgery could be performed in four patients among five with LAD. At the median follow-up of 10 months, the median progression-free survival (PFS) and overall survival (OS) of the entire cohort of patients were 7.4 and 12.1 months, respectively. Dose modification was done in 12 patients due to toxicity in 8 and noncompliance in 4 patients. The most common hematological toxicity was neutropenia, which occurred at grade 3-4 intensity in 10 of 54 patients (27.7%). Febrile neutropenia was diagnosed only in two cases. Conclusions: DCX regimen offers prominent anti-tumor activity and considered to be effective firstline treatment with manageable toxicity for patients with HER2-negative advanced gastric cancer.
  • Küçük Resim Yok
    Öğe
    Modified docetaxel and cisplatin in combination with capecitabine (DCX) as first-tine treatment in HER2-negative advanced gastric cancer
    (American Society of Clinical Oncology, 2014) Bilici, Ahmet; Selçukbiricik, Fatih; Demir, Nazan; Öven Ustaalioğlu, Bala Başak; Dikillitaş, Mustafa; Yıldız, Özcan
    [Abstract Not Available]